“At Sylvester, we are currently evaluating the genomic landscape and role of circulatory biomarkers to better risk-stratify and track treatment response at a molecular level in patients with Secondary Central Nervous System Lymphoma,” said Juan Alderuccio, MD, a Sylvester hematologist and lymphoma specialist. “Our lymphoma group is also developing clinical trials in this difficult-to-treat population to improve outcomes.”